📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

AstraZeneca PLC (AZNm)

Buenos Aires
Currency in ARS
Disclaimer
46,800.000
-725.000(-1.53%)
Closed
AZNm Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
46,800.00047,450.000
52 wk Range
17,650.00058,050.000
Bid/Ask
46,800.00 / 46,950.00
Prev. Close
47,525
Open
47,225
Day's Range
46,800-47,450
52 wk Range
17,650-58,050
Volume
149
Average Volume (3m)
564
1-Year Change
61.38%
Fair Value
Unlock
Fair Value Upside
Unlock
AZNm Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
18,573.700
Upside
+58.155%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

AstraZeneca PLC Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
89900

Compare AZNm to Peers and Sector

Metrics to compare
AZNm
Peers
Sector
Relationship
P/E Ratio
37.2x16.0x−0.6x
PEG Ratio
8.710.060.00
Price/Book
6.1x3.7x2.6x
Price / LTM Sales
4.9x2.5x3.2x
Upside (Analyst Target)
-80.2%46.5%
Fair Value Upside
Unlock7.9%6.6%Unlock

FAQ

What Is the AstraZeneca (AZNm) Stock Price Today?

The AstraZeneca stock price today is 46,800.00.

What Stock Exchange Does AstraZeneca Trade On?

AstraZeneca is listed and trades on the Buenos Aires stock exchange.

What Is the Stock Symbol for AstraZeneca?

The stock symbol for AstraZeneca is "AZNm."

Does AstraZeneca Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 1.37%.

What Is the AstraZeneca Market Cap?

As of today, AstraZeneca market cap is 232.16T.

What is AstraZeneca Earnings Per Share?

The AstraZeneca EPS is 4.16.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.